Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors
Joint Authors
Dragovich, Tomislav
Youssef, Alexey
Kasso, Nawara
Torloni, Antonio Sergio
Stanek, Michael
Gimbel, Mark
Mahmoud, Fade
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-12-20
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Ipilimumab is a monoclonal antibody that enhances the efficacy of the immune system by targeting a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is a protein receptor that downregulates the immune system.
Nivolumab is also a humanized monoclonal antibody that targets another protein receptor that prevents activated T cells from attacking the cancer; this receptor is called programmed cell death 1 (PD-1).
The FDA approved ipilimumab combined with nivolumab as a frontline therapy for patients with metastatic melanoma or renal cell carcinoma and as a second-line therapy for patients with microsatellite instability-high (MSI-H) metastatic colon cancer.
Immune-related adverse events such as autoimmune colitis, pneumonitis, hepatitis, nephritis, hypophysitis, and thyroiditis may occur during or weeks to months after therapy.
We report a case of thrombotic thrombocytopenic purpura (TTP) in a patient with metastatic renal cell carcinoma following one cycle of ipilimumab and nivolumab.
Only one case report of ipilimumab-induced TTP exists in the medical literature.
With the wide use of immunotherapy to treat cancers, physicians need to be aware of this rare immune-related adverse event.
American Psychological Association (APA)
Youssef, Alexey& Kasso, Nawara& Torloni, Antonio Sergio& Stanek, Michael& Dragovich, Tomislav& Gimbel, Mark…[et al.]. 2018. Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors. Case Reports in Hematology،Vol. 2018, no. 2018, pp.1-4.
https://search.emarefa.net/detail/BIM-1143770
Modern Language Association (MLA)
Youssef, Alexey…[et al.]. Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors. Case Reports in Hematology No. 2018 (2018), pp.1-4.
https://search.emarefa.net/detail/BIM-1143770
American Medical Association (AMA)
Youssef, Alexey& Kasso, Nawara& Torloni, Antonio Sergio& Stanek, Michael& Dragovich, Tomislav& Gimbel, Mark…[et al.]. Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors. Case Reports in Hematology. 2018. Vol. 2018, no. 2018, pp.1-4.
https://search.emarefa.net/detail/BIM-1143770
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1143770